Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 142 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Withdrawal Syndrome Clear all
Recruiting Phase 3 Interventional

Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

NCT05834478
View directory record Official record
Conditions
Withdrawal Symptoms, Opioid Use Disorder, Opioid Use
Interventions
Transcutaneous Cervical Vagal Nerve Stimulation, Sham Stimulation, [F-18]Fallypride
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 1 Interventional

Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

NCT00521248
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
buprenorphine, Oral morphine solution
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Not applicable Interventional

Use of SVS Device to Improve Outcomes for Neonatal Opioid Withdrawal Syndrome.

NCT04834297
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Prapela SVS mattress
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
0 Days to 2 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal

NCT00480441
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Dronabinol, BRENDA therapy, Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Not applicable Interventional

The Effect of Self-Forgiveness on Self-Stigma in Addiction.

NCT03971097
View directory record Official record
Conditions
Substance Use Disorders, Opiate Dependence, Opiate Withdrawal Syndrome, Opioid-use Disorder, Alcohol Withdrawal, Alcohol Abuse, Alcohol Use Disorder, Cocaine Abuse, Cocaine Use Disorder, Cocaine Withdrawal, Benzodiazepine Abuse, Benzodiazepine Dependence, Substance Abuse, Heroin Overdoses, Heroin Withdrawal, Heroin Abuse
Interventions
Six Step Model of Self-Forgiveness, Treatment as Usual (TAU)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
McKeesport, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jul 21, 2026, 11:42 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT04666610
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years to 25 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

NCT03697109
View directory record Official record
Conditions
Cushing Syndrome
Interventions
Relacorilant, Placebo
Drug · Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Los Angeles, California • Torrance, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Music Therapy on Newborns

NCT03987165
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Substance Withdrawal, Neonatal
Interventions
Music Therapy
Other
Lead sponsor
Tulane University
Other
Eligibility
1 Minute to 1 Month
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 1 Interventional

Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients

NCT01650649
View directory record Official record
Conditions
Opioid Dependence, Methadone Withdrawal Syndrome
Interventions
Lofexidine HCl, Lofexidine-matching sugar pill
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

NCT01592747
View directory record Official record
Conditions
Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome, Autism Spectrum Disorders, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl), Placebo capsules
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
64
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jul 21, 2026, 11:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Qualitative Understanding of Experiences With the SIMPLIFY Trial

NCT04320381
View directory record Official record
Conditions
Cystic Fibrosis, Drug Withdrawal
Interventions
Qualitative Interview
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 4 Interventional Results available

Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome

NCT04298853
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal, Neonatal Opioid Withdrawal Syndrome
Interventions
Morphine PRN, Morphine scheduled
Drug
Lead sponsor
Indiana University
Other
Eligibility
Up to 28 Days
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

THC Crossover Study

NCT04429568
View directory record Official record
Conditions
THC, Cannabis, Cannabis Smoking, Cannabis Use, Unspecified, Cigarette Smoking, Tobacco Use, Nicotine Dependence, Nicotine Withdrawal, Cardiovascular Risk Factor
Interventions
Smoked Cannabis, Vaped Cannabis, Tobacco Cigarette
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED

NCT02643355
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
Olanzapine, Clonidine
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Jul 21, 2026, 11:42 AM EDT
Not listed Phase 2 Interventional

Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder

NCT04850664
View directory record Official record
Conditions
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Withdrawal Symptoms, Craving, Negative Affectivity
Interventions
CBOT + TAU, Sham + TAU
Drug
Lead sponsor
Evon Medics LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal

NCT01863186
View directory record Official record
Conditions
Opioid Dependence, Acute Opioid Withdrawal Syndrome
Interventions
Lofexidine HCl, Placebo, Open Label Lofexidine HCL
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Clovis, California • Escondido, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome

NCT01325220
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
arbaclofen, Placebo
Drug
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Eligibility
5 Years to 11 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Long Beach, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Not applicable Interventional

A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)

NCT00001008
View directory record Official record
Conditions
HIV Infections
Interventions
Methadone hydrochloride, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Jul 21, 2026, 11:42 AM EDT
Completed No phase listed Observational

AduLt iatrogEnic withdRawal sTudy in the ICU (ALERT-ICU)

NCT04422808
View directory record Official record
Conditions
Withdrawal Syndrome, Iatrogenic Disease
Interventions
Not listed
Lead sponsor
Wilkes University
Other
Eligibility
18 Years and older
Enrollment
2,437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 1 Interventional

Pilot Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients

NCT01558934
View directory record Official record
Conditions
Opioid Dependence, Methadone Withdrawal Syndrome
Interventions
Lofexidine HCl
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 3 Interventional

Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach

NCT05980260
View directory record Official record
Conditions
Neonatal Opiate Withdrawal Syndrome
Interventions
Symptom-based Dosing Approach, Scheduled Opioid Taper Approach
Other
Lead sponsor
HELP for NOWS Consortium
Network
Eligibility
1 Hour to 48 Hours
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Wilmington, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 1 Interventional

Acute Withdrawal From Smoked Cocaine - 9

NCT00000292
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance Withdrawal Syndrome, Substance-Related Disorders
Interventions
Cocaine
Procedure
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

NCT03277690
View directory record Official record
Conditions
Endogenous Cushing's Syndrome
Interventions
Levoketoconazole, Placebo
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jul 21, 2026, 11:42 AM EDT